We can provide GMP validation service that complies with SFDA, FDA, WHO and EU EMPA.Excellent registration team could help us easlily to register our products in different countries.If you and your customer are interested in some products or need CMO business service because of capacity limit, product cost limit or developing limit, plz feel free to contact us. 

Besides, we could discuss the possible FDF distribution business. Hope to get the chance to discuss deeply.

Hangzhou Jinlan Pharm-Drugs Technology Co., Limited  is located in Hangzhou, Zhejiang Province. Neighboring Ningbo port, Shanghai port, Hangzhou Xiaoshan Int’l Airport and Shanghai Pudong Int’l Airport, the transportation and production environment are excellent.

We have established well market channels both domestically and overseas. Now JINLAN PHARMA is authorized by some Chinese chemical factories as universal agency and international area agency. Our products are exported to more than 100 countries and enjoy a well reputation, including Europe, USA, South America, India, south-east Asia and so on. Such as Canada, Germany, Spain, Australia, Russia, UAE, Estonia, Indonesia, Egypt, Pakistan and so on. Our machines with Excellent quality, Competitive price, Good after-service, are highly welcomed by our customers. We are pleased to know you and hope to be good friend and cooperator with you for our products. I am sure you will be satisfied with us.

Based on the philosophy of “Human-orient, Technical first, Quality product and High efficiency, Fact and Innovation”, JINLAN PHARMA highly welcome friends from all over the world to cooperate and get co-development. 

Description

Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. It exerts its antiarrhythmic effect by induction of slow inward sodium current, which prolongs action potential and refractory period (physiology) of myocardial cells. Because of its Class III antiarrhythmic activity, there should not be concomitant administration of Class Ia and Class III agents.
Ibutilide is marketed as Corvert by Pfizer. Administration resulted in successful heart rhythm control in 31-44% of patients within 90 minutes, with sustained polymorphic ventricular tachycardia in 0.9-2.5% of patients. It appears to show better results in atrial flutter as compared to atrial fibrillation.

Basic Info

Numbering system

Properties

Safety Info